Engineers at the University of California San Diego have developed neutrophil “nanosponges” that can safely absorb and neutralize a variety of proteins that play a role in the progression of rheumatoid arthritis. Injections of these nanosponges effectively treated severe rheumatoid arthritis in two mouse models. Administering the nanosponges early on also prevented the disease from developing.
The work is published Sept. 3 in Nature Nanotechnology.
“Nanosponges are a new paradigm of treatment to block pathological molecules from triggering disease in the body,” said senior author Liangfang Zhang, a nanoengineering professor at the UC San Diego Jacobs School of Engineering. “Rather than creating treatments to block a few specific types of pathological molecules, we are developing a platform that can block a broad spectrum of them, and this way we can treat and prevent disease more effectively and efficiently.”
This work is one of the latest examples of therapeutic nanosponges developed by Zhang’s lab. Zhang, who is also affiliated with the Institute of Engineering in Medicine and Moores Cancer Center at UC San Diego, and his team previously developed red blood cell nanosponges to combat and prevent MRSA infections and macrophage nanosponges to treat and manage sepsis.
The new nanosponges are nanoparticles of biodegradable polymer coated with the cell membranes of neutrophils, a type of white blood cell.
Neutrophils are among the immune system’s first responders against invading pathogens. They are also known to play a role in the development of rheumatoid arthritis, a chronic autoimmune disease that causes painful inflammation in the joints and can ultimately lead to damage of cartilage and bone tissue.
When rheumatoid arthritis develops, cells in the joints produce inflammatory proteins called cytokines. Release of cytokines signals neutrophils to enter the joints. Once there, cytokines bind to receptors on the neutrophil surfaces, activating them to release more cytokines, which in turn draws more neutrophils to the joints and so on.
The nanosponges essentially nip this inflammatory cascade in the bud. By acting as tiny neutrophil decoys, they intercept cytokines and stop them from signaling even more neutrophils to the joints, reducing inflammation and joint damage.
These nanosponges offer a promising alternative to current treatments for rheumatoid arthritis. Some monoclonal antibody drugs, for example, have helped patients manage symptoms of the disease, but they work by neutralizing only specific types of cytokines. This is not sufficient to treat the disease, said Zhang, because there are so many different types of cytokines and pathological molecules involved.
“Neutralizing just one or two types might not be as effective. So our approach is to take neutrophil cell membranes, which naturally have receptors to bind all these different types of cytokines, and use them to manage an entire population of inflammatory molecules,” said Zhang.
“This strategy removes the need to identify specific cytokines or inflammatory signals in the process. Using entire neutrophil cell membranes, we’re cutting off all these inflammatory signals at once,” said first author Qiangzhe Zhang, a Ph.D. student in Professor Liangfang Zhang’s research group at UC San Diego.
To make the neutrophil nanosponges, the researchers first developed a method to separate neutrophils from whole blood. They then processed the cells in a solution that causes them to swell and burst, leaving the membranes behind. The membranes were then broken up into much smaller pieces. Mixing them with ball-shaped nanoparticles made of biodegradable polymer fused the neutrophil cell membranes onto the nanoparticle surfaces.
“One of the major challenges of this work was streamlining this entire process, from isolating neutrophils from blood to removing the membranes, and making this process repeatable. We spent a lot of time figuring this out and eventually created a consistent neutrophil nanosponge production line,” said Qiangzhe Zhang.
In mouse models of severe rheumatoid arthritis, injecting nanosponges in inflamed joints led to reduced swelling and protected cartilage from further damage. The nanosponges performed just as well as treatments in which mice were administered a high dose of monoclonal antibodies.
The nanosponges also worked as a preventive treatment when administered prior to inducing the disease in another group of mice.
Professor Liangfang Zhang cautions that the nanosponge treatment does not eliminate the disease. “We are basically able to manage the disease. It’s not completely gone. But swelling is greatly reduced and cartilage damage is minimized,” he said.
The team hopes to one day see their work in clinical trials.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Reumatoid arthritis
- European advisory group backs AbbVie's upadacitinib for rheumatoid arthritison October 18, 2019 at 4:47 am
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of AbbVie's (NYSE:ABBV) JAK inhibitor RINVOQ (upadacitinib), as monotherapy or with ...
- BRIEF-AbbVie Receives CHMP Positive Opinion For Upadacitinib (RINVOQ) For Treatment Of Adults With Moderate To Severe Active Rheumatoid Arthritison October 18, 2019 at 4:44 am
Oct 18 (Reuters) - Abbvie Inc: * ABBVIE RECEIVES CHMP POSITIVE OPINION FOR UPADACITINIB (RINVOQ™) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS * ABBVIE INC - CHMP ...
- AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ™) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritison October 18, 2019 at 4:30 am
The positive opinion is for use of upadacitinib as monotherapy or in combination with methotrexate. The CHMP positive opinion is supported by data from the global Phase 3 SELECT rheumatoid arthritis ...
- Know here how early detection of rheumatoid arthritis is possibleon October 15, 2019 at 4:20 am
Rheumatoid arthritis is an autoimmune disease in which the immune system of the body (that’s responsible of attacking disease-causing foreign objects) mistakenly starts attacking the joints. This ...
- Noble’s Self-Injection Trainers for Rheumatoid Arthritis Drugs: Interview with Joe Reynolds, Research Manageron October 14, 2019 at 8:30 am
At the time, Joe Reynolds, Research Manager at Noble International, shared some use cases for the company’s products, including rheumatoid arthritis (RA). Since that interview, longitudinal data has ...
- Women more prone to rheumatoid arthritis than men, says experton October 12, 2019 at 8:14 pm
Rheumatoid arthritis has a prevalence of about 1 per cent worldwide and can affect people of all age groups, including children and adolescents. Women are more prone to get affected than men, said ...
- World Arthritis Day 2019: Know The Link Between Rheumatoid Arthritis And Depressionon October 11, 2019 at 10:50 pm
A person with rheumatoid arthritis (RA) may not seem to fit the usual profile of an "arthritis" patient since this word is usually associated with older people. RA, however, is a type of arthritis ...
- Women are more likely to be affected with Rheumatoid Arthritis (RA) than menon October 11, 2019 at 1:14 am
Rheumatoid Arthritis is a chronic, debilitating disease that causes a major impact on a patient’s quality of life and socio-economic productivity. RA affects about 1 per cent of the total population.
- Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritison October 10, 2019 at 3:44 pm
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, ...
- Danielle Collins reveals diagnosis of rheumatoid arthritison October 10, 2019 at 2:48 am
Danielle Collins has begun treatment for rheumatoid arthritis, a chronic inflammatory condition that causes pain and swelling in the body's joints. The American, 25, who is the WTA World No.33 and ...
via Bing News